{
  "docId": "019de072-a701-779d-b9c1-29622b36dd41",
  "docSlug": "f2c95dae10c304072442cd11deed84ec",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 53 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 11,
  "pageCount": 53,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 16,
  "notes": "Includes footnotes regarding Bausch Health name change and non-GAAP measures.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-a701-779d-b9c1-29622b36dd41/11",
  "deckHref": "/decks/019de072-a701-779d-b9c1-29622b36dd41",
  "deckJsonHref": "/decks/019de072-a701-779d-b9c1-29622b36dd41.json",
  "deckAnchorHref": "/decks/019de072-a701-779d-b9c1-29622b36dd41#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Revenue Breakdown by segment",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc497d9c-5faf-4d74-a4a8-8b93c2984616",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.25,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "1. Bausch Health will assume a new name at some point in the future. 2. This is a non-GAAP measure or non-GAAP ratio.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be163cac-53d1-4ca0-9167-f7b93aa5d11b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.48
      },
      "kind": "list",
      "text": "International: Revenue -20% due to Amoun divestiture; 8% organic growth.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c351a3f-aee5-4ac0-a585-e6aaa859b50a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.62
      },
      "kind": "list",
      "text": "Diversified Products: 14% growth; unfavorable comparisons for Pepcid, Ativan, Mysoline.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0cad5ca6-ff98-4ea7-8d7e-2417cdb90ef0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Salix: 1Q revenue decline -2%, driven by lower volumes; TRx volume growth in Trulance, Relistor, Xifaxan, PLENVU; Market share gains.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b8dda2e-bc72-4bdc-8b05-4243f66ae87a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "list",
      "text": "Solta Medical: Flat organic revenue due to China lockdowns and supply constraints.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8760e1cb-c544-4b98-95e2-ddd9bfef9a75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.55,
        "y": 0.65
      },
      "kind": "metric",
      "text": "1Q22 Reported Revenue: (10%)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4be597c1-a586-4fbe-99a1-dc332631a00b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.55,
        "y": 0.78
      },
      "kind": "metric",
      "text": "1Q22 Organic Revenue: (3%)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f07c708d-a44a-4756-a00a-7c88bf7f0272",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.55,
        "x": 0.18,
        "y": 0.05
      },
      "kind": "title",
      "text": "Bausch Pharma/Solta 1Q22 Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e213d93-63ed-472e-89d2-801058c89f67",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "c0f86b64-ce59-406d-a423-174049cdd55f",
      "evidence": "list/bullet: Salix: 1Q revenue decline -2%, driven by lower volumes; TRx volume growth in Trulance, Relistor, Xifaxan, PLENVU; Market share gains.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 19,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7720718b-ea2d-4109-9564-eb09c0194463",
      "evidence": "Financial results and leverage discussion",
      "position": 0,
      "objective": "Highlighting the need for strategic alternatives",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}